Recent studies have also found that when FAM83A is knocked down, it increases trastuzumab sensitivity in drug-resistant cells and may be a target for the development of clinical diagnostic or therapeutic strategies to guide the treatment of patients with HER2+ breast cancer who have developed trastuzumab resistance (Boyer et al., 2013). This evidence concerns the gene ERBB2 and breast cancer.